Genscript Biotech Corporation

DB:G51 Stock Report

Market Cap: €2.6b

Genscript Biotech Past Earnings Performance

Past criteria checks 0/6

Genscript Biotech's earnings have been declining at an average annual rate of -8.7%, while the Life Sciences industry saw earnings growing at 13.9% annually. Revenues have been growing at an average rate of 26.5% per year.

Key information

-8.7%

Earnings growth rate

-6.4%

EPS growth rate

Life Sciences Industry Growth26.8%
Revenue growth rate26.5%
Return on equity-17.8%
Net Margin-17.5%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Genscript Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

DB:G51 Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 241,010-177424462
31 Mar 24925-136408447
31 Dec 23840-95393433
30 Sep 23773-140383426
30 Jun 23707-185374420
31 Mar 23667-206363405
31 Dec 22626-227352390
30 Sep 22598-315354375
30 Jun 22570-403356361
31 Mar 22530-381330360
31 Dec 21490-359303358
30 Sep 21483-265270341
30 Jun 21454-183235323
31 Mar 21422-194216293
31 Dec 20391-205197263
30 Sep 20354-194171251
30 Jun 20318-183146239
31 Mar 20296-140136212
31 Dec 19273-97126186
30 Sep 19257-59112148
30 Jun 19241-2298109
31 Mar 1923608992
31 Dec 18231217974
30 Sep 18216247258
30 Jun 18201276541
31 Mar 18177265630
31 Dec 17153264718
30 Sep 17139274811
30 Jun 1712528495
31 Mar 1712027502
31 Dec 1611526510
30 Sep 1610726500
30 Jun 169925480
31 Mar 169321470
31 Dec 158718460
30 Sep 158213430
30 Jun 15788390
31 Mar 15747380
31 Dec 14706370
31 Dec 13606290

Quality Earnings: G51 is currently unprofitable.

Growing Profit Margin: G51 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: G51 is unprofitable, and losses have increased over the past 5 years at a rate of 8.7% per year.

Accelerating Growth: Unable to compare G51's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: G51 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-1.4%).

Return on Equity

High ROE: G51 has a negative Return on Equity (-17.82%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 13:43
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Genscript Biotech Corporation is covered by 21 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Linda LuBOCI Research Ltd.
Jin ZhangChina International Capital Corporation Limited
Yue-Kwong LuiChina Renaissance Securities